Lifescience Dynamics https://validator.w3.org/feed/docs/rss2.html Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission Company culture ASRS 2026 and the reshaping of advanced AMD About us Team Why Lifescience Dynamics? ESHRE 2026: How reproductive ageing, personalisation and AI are reshaping fertility care Today marks World Lung Cancer Day, an opportunity to raise awareness of the most commonly… The next era of HIV care: How long-acting innovation is redefining treatment and prevention From valency to vaccine design: The changing competitive landscape in Pneumococcal vaccines Current trends and the renaissance of Alzheimer’s drug development Gutsy moves in the IBD biologics market Driving CAR-Ts for Treatment in Cancer and Immunology From Lab to Leadership: Navigating Biotech’s New Wave with Dr. Vicki Tsao Alaa Alsaafin: Pioneering Paths in Pharma for Muslim Women Breaking Barriers: The Inspiring Story of Dr. Minori Yoshida, from Island Girl to Big Pharma Pharma Strategies for Succeeding Amid Strong Headwinds How I built a global business on a budget of just £7,500 AI-Generated Drug Candidates Are Here, But Clinical Trial Wins Need More Time Lifescience Dynamics: How This Rapidly Growing Support Consultancy Helps Clients Make Better Decisions Quest For Alzheimer’s Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning What lessons will you take forward into the new year and how will you apply these teachings to your business strategy? 2023 reflections and 2024 predictions for the pharmaceutical industry Precision medicine: Cutting through the complexity Overcoming diagnosis delays in Alzheimer’s: Why the development of biomarkers is critical to the success of future treatments Behind big pharma is big intelligence How Competitive Intelligence “Detectives” Gather Data for Pharmaceutical Brands Pharma comment: Notes from an evolving landscape for innovation Rare diseases: Challenges and hope for the future Did the FTC get it wrong when it blocked the Sanofi-Maze deal? Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? Pushing the boundaries in cell therapy: CAR-T updates from EHA 2025 RNA Therapeutics As We Enter 2025: Looking Beyond The Horizon Of First-Generation Success In her own words: From Saipan to NYC, Minori Yoshida’s career Rafaat Rahmani: Beating the Odds Leading Pharmaceutical Decision Support Firm Lifescience Dynamics Appoints Vice-President Targeted therapies, key subgroup insights to watch at ASH 2025 Reshaping kidney care: Q&A with Stylianos Sarrigiannidis How are the rare disease evidence principles reshaping evidentiary expectations? Lipid lowering with PCSK9 inhibition: Long-term efficacy, long-standing barriers The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer Beyond JAK inhibitors: Biologics signal a new era in Alopecia Areata The changing multiple sclerosis landscape: Earlier diagnosis, improved monitoring, and a more competitive race for durable disease control Parkinson’s disease: Transitioning from symptom control to disease modification Home Rare disease at an inflection point: Why the next wave will be won on strategic insight US pharma MFN and tariff dynamics: What EU and UK leaders need to know GLP-1s in CKD: Evidence, market leadership, and key insights from ASN 2025 Advances in breast cancer: What’s new from ESMO 2025 Press